4:15 PM
 | 
Oct 15, 2013
 |  BC Extra  |  Company News

XenoPort investor wants new CEO, strategy

XenoPort Inc. (NASDAQ:XNPT) investor Clinton Group Inc. said the biotech's CEO Ronald Barrett should resign and called for a shift in the company's focus to XP23829, which is in Phase I testing for relapsing-remitting multiple sclerosis (RRMS) and in preclinical development for psoriasis. In a letter to Barrett, Clinton Group said XenoPort's Horizant gabapentin enacarbil -- which is approved...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >